1-[2-(Trifluoromethyl)pyrimidin-5-yl]cyclohexane-1-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 1-[2-(Trifluoromethyl)pyrimidin-5-yl]cyclohexane-1-carboxamide
• 英文别名: 1-[2-(trifluoromethyl)pyrimidin-5-yl]cyclohexane-1-carboxamide
• 化学式: C₁₂H₁₄F₃N₃O
• 分子量: 273.25
• InChiKey: RBGGJPJKMWXFGK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  68.9
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• [EN] INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS D'INDOLE CARBOXAMIDE UTILISÉS EN TANT QU'ANTAGONISTES DU RÉCEPTEUR P2X7
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2014097140A1

  公开（公告）日：2014-06-26

  The invention relates to indole carboxamide derivatives of formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and n are as defined in the description, their preparation and their use as pharmaceutically active compounds.

  这项发明涉及式(I)的吲哚羧酰胺衍生物，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10和n如描述中所定义，它们的制备以及它们作为药用活性化合物的用途。
• INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：US20150344425A1

  公开（公告）日：2015-12-03

  The invention relates to indole carboxamide derivatives of formula (I), wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and n are as defined in the description, their preparation and their use as pharmaceutically active compounds.

  该发明涉及式(I)的吲哚羧酰胺衍生物，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10和n如描述中所定义，它们的制备以及它们作为药物活性化合物的用途。
• P2X7 receptor antagonists for restoring T-cell lymphopoiesis in subjects infected with human immunodeficiency virus (HIV)
  申请人：INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)

  公开号：US10548980B2

  公开（公告）日：2020-02-04

  The present invention relates to pharmaceutical composition and uses thereof for restoring T-cell lymphopoiesis in subjects infected with human immunodeficiency virus (HIV). In particular, the present invention relates to a P2X7 receptor antagonist for use in a method of restoring T-cell lymphopoiesis in a subject infected with human immunodeficiency virus (HIV) comprising administering to the subject a therapeutically effective amount of said P2X7 receptor antagonist.

  本发明涉及用于恢复感染人类免疫缺陷病毒（HIV）的受试者的T细胞淋巴细胞生成的药物组合物及其用途。特别是，本发明涉及一种P2X7受体拮抗剂，用于在感染了人类免疫缺陷病毒（HIV）的受试者中恢复T细胞淋巴细胞生成的方法，该方法包括向受试者施用治疗有效量的所述P2X7受体拮抗剂。
• P2X7 RECEPTOR ANTAGONISTS FOR RESTORING T-CELL LYMPHOPOIESIS IN SUBJECTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV)
  申请人：INSERM (Institut National de la Santé et de la Recherche Médicale)

  公开号：EP3402469B1

  公开（公告）日：2021-01-06
• US9556117B2
  申请人：——

  公开号：US9556117B2

  公开（公告）日：2017-01-31